TheFly.com
Start Free Trial
<
Back to all Breaking News
OVID
12/17/2018 06:12am
4
Street Research Stories
chevron_right
Ovid Therapeutics: Phase 1b/2a trial of OV935/TAK-935 met primary endpoint
Don't miss out!
We read the Wall Street research, SEC filings and press releases so you don't have to.
Sign up for our 14-day free trial to read this story.
Join Now
Learn More
Already have an account?
Sign In Here
Subscription Rates
dynamic_feed
Breaking News
search
Search
menu
Menu
